[AsCNP_P23] ポスター23
Schizophrenia 2

[AsCNP-P23-2] Symptomatic and functional response to brexpiprazole treatment in patients with acute schizophrenia by age

^○Catherine WEISS¹, Erin MACKENZIE², Francois THERRIEN³, Peter ZHANG⁴, Stine Rasmussen MEEHAN⁵ (1. Department of Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., 2. Department of Medical Affairs, Lundbeck Canada Inc., 3. Department of Medical Affairs, Otsuka Canada Pharmaceutical Inc., 4. Department of Biostatistics, Otsuka Pharmaceutical Development & Commercialization Inc, 5. Department of Medical Affairs Psychiatry, H. Lundbeck A/S)